1. Home
  2. FAC vs CTNM Comparison

FAC vs CTNM Comparison

Compare FAC & CTNM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Factorial Energy Inc. Class A Common Stock

FAC

Factorial Energy Inc. Class A Common Stock

N/A

Current Price

$5.41

Market Cap

561.9M

Sector

Miscellaneous

ML Signal

N/A

Logo Contineum Therapeutics Inc.

CTNM

Contineum Therapeutics Inc.

HOLD

Current Price

$15.42

Market Cap

550.7M

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
FAC
CTNM
Founded
N/A
2009
Country
United States
United States
Employees
N/A
N/A
Industry
Industrial Machinery/Components
Sector
Miscellaneous
Exchange
Nasdaq
Nasdaq
Market Cap
561.9M
550.7M
IPO Year
2025
2024

Fundamental Metrics

Financial Performance
Metric
FAC
CTNM
Price
$5.41
$15.42
Analyst Decision
Buy
Analyst Count
0
4
Target Price
N/A
$19.00
AVG Volume (30 Days)
460.0K
243.7K
Earning Date
N/A
05-13-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
0.46
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$4.24
$5.71
52 Week High
$15.40
$16.91

Technical Indicators

Market Signals
Indicator
FAC
CTNM
Relative Strength Index (RSI) 27.98 50.66
Support Level $4.27 $13.62
Resistance Level $5.76 $15.52
Average True Range (ATR) 0.65 1.03
MACD 0.15 -0.02
Stochastic Oscillator 49.55 38.30

Price Performance

Historical Comparison
FAC
CTNM

About FAC Factorial Energy Inc. Class A Common Stock

Factorial Energy Inc is an American solid-state battery innovator backed by In-Q-Tel - the not-for-profit strategic investor for the U.S. national security community and America's allies - and Mercedes-Benz, Stellantis, Hyundai, and Kia. Through its proprietary FEST and Solstice platforms, engineered for scalable manufacturing, it delivers industry performance across defense, space, and energy storage applications. Mercedes-Benz's real-world road testing in a lightly modified test vehicle achieved over 1,200 km of range on a single charge, while Stellantis-lab testing verified 77 Ah cells demonstrating high energy density, fast-charging, and robust use for energy and power performance across temperature extremes.

About CTNM Contineum Therapeutics Inc.

Contineum Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the development of oral small-molecule therapies for neurological, inflammatory, and immunological conditions. The company focuses on developing selective compounds targeting challenging molecular pathways and has built a portfolio of small molecule drug candidates. Its pipeline includes drug candidates in clinical development, such as PIPE-791, an LPA1 receptor antagonist being studied for idiopathic pulmonary fibrosis and chronic pain, and PIPE-307, an M1 receptor inhibitor being evaluated for relapsing-remitting multiple sclerosis and other depressive disorders.

Share on Social Networks: